T. Rowe Price Investment Management, Inc. Repligen Corp Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Repligen Corp stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 159,057 shares of RGEN stock, worth $22.2 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
159,057
Previous 27,710
474.01%
Holding current value
$22.2 Million
Previous $4.12 Million
455.16%
% of portfolio
0.01%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding RGEN
# of Institutions
482Shares Held
56.3MCall Options Held
251KPut Options Held
458K-
Black Rock Inc. New York, NY7.57MShares$1.05 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.14MShares$994 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.1MShares$711 Million0.01% of portfolio
-
State Street Corp Boston, MA1.69MShares$236 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.54MShares$215 Million1.48% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $7.73B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....